-
In this module, Jordan J. Feld, MD, MPH, and Hemant Shah, MD, MScCH HPTE, review optimal strategies for managing patients with hepatitis C virus infection.
-
Led by Norah Terrault, MD, MPH, a panel of experts including Gregory Dore, MBBS, PhD, FRACP, MPH; Graham R. Foster, FRCP, PhD; and Ira M. Jacobson, MD, provides an overview of the current state of HCV therapy, emphasizing the unprecedented levels of efficacy and simplicity in curing individual patients, and discusses important strategies for eliminating HCV infection across communities and ultimately throughout the world.
-
In this downloadable slideset, Sherilyn C. Brinkley, MSN, CRNP; Jordan J. Feld, MD, MPH; Jason Grebely, BSc, PhD; Nancy Reau, MD, FAASLD, AGAF; and Phoebe Sebhatu, PharmD, BCPS, review best practices in addressing practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient education and engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of drug users and patients who become reinfected.
-
Listen to this downloadable audio from a live Webinar in which an expert faculty member discusses the clinical impact of new data reported at the Barcelona meeting.
-
In this downloadable slideset, Ira M. Jacobson, MD, reviews the newest regimens and data for genotype 1 HCV infection.
|
Latest Content
-
In this downloadable slideset, Ira M. Jacobson, MD, and Norah Terrault, MD, MPH, provide a comprehensive update on current and near-future HCV management.
Date Posted: 6/16/2017
-
In this downloadable slideset, David L. Wyles, MD, provides a comprehensive overview of available data and guideline recommendations on retreatment of HCV infection in patients who experienced previous DAA failure.
Date Posted: 6/16/2017
-
| Paul Y. Kwo MD - 5/25/2017 |
4 comments / Last Comment: 6/14/2017 |
Here’s my take on new data from EASL 2017.
-
| Nancy Reau MD, FAASLD, AGAF - 5/12/2017 |
6 comments / Last Comment: 6/23/2017 |
Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.
-
In this downloadable slideset, expert faculty members Paul Y Kwo, MD, Nancy Reau, MD, FAASLD, AGAF, and Stefan Zeuzem, MD, highlight key studies from this important annual conference.
Date Posted: 5/9/2017
-
Stefan Zeuzem, MD, provides a rapid update on the key hepatology studies anticipated to affect clinical practice.
Date Posted: 5/2/2017
-
100% SVR12 rates observed in patients who previously failed NS3/4A PI regimens; lowest SVR12 rates of 79% to 81% observed in patients who failed both NS3/4A PI and NS5A inhibitor regimens.
Date Posted: 4/25/2017
-
Ribavirin-free regimen noninferior to current standard-of-care DAA regimens and well tolerated in this challenging-to-treat patient population.
Date Posted: 4/25/2017
-
Novel fixed-dose combination regimen effective in both cirrhotic and noncirrhotic patients with no serious drug-related adverse events or toxicity-driven discontinuations.
Date Posted: 4/24/2017
-
The SVR12 rate for 8 weeks of glecaprevir/pibrentasvir was noninferior to 12 weeks, which was noninferior to the rate achieved with standard-of-care sofosbuvir plus daclatasvir for 12 weeks.
Date Posted: 4/24/2017
|
|
|